Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization

Purpose  

To determine the incidence and features of macular retinal detachment (RD) after successful intravitreal injection of bevacizumab (IVB) for the treatment of myopic choroidal neovascularizations (CNVs).     

Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]

Background  

To assess the effect of intravitreal triamcinolone acetonide (iTA) as an adjunctive treatment to transpupillary therapy (TTT) for new subfoveal choroidal neovascular membranes (CNV) in age-related macular degeneration (AMD).     

Choroidal neovascularization in a patient with blunt trauma-caused traumatic retinopathy without choroidal rupture

Purpose  

To report a case of choroidal neovascularization (CNV) following blunt trauma without choroidal rupture, with past history of central serous chorioretinopathy (CSC).     

Correlation between cross-sectional shape of choroidal veins and choroidal thickness

Purpose  

To determine whether a significant correlation exists between the ratio of the vertical and horizontal diameters of the choroidal veins and the choroidal thickness in normal eyes.     

Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy

Purpose  

To investigate the characteristics of eyes with polypoidal choroidal vasculopathy (PCV) which develop secondary classic choroidal neovascularization (CNV) after photodynamic therapy (PDT).     

Choroidal thickness measurement in healthy Japanese subjects by three-dimensional high-penetration optical coherence tomography

Background  

We performed retinal and choroidal thickness mapping by three-dimensional high-penetration optical coherence tomography (OCT) and evaluated the choroidal thickness distribution throughout the macula in healthy eyes.     

One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups

Purpose  

To report 1-year clinical outcomes of intravitreal ranibizumab treatment for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) and to identify predictive factors that may influence visual acuity (VA) outcomes in Korean patients.     

Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy

Purpose  

To investigate the subfoveal choroidal thickness in eyes with typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV), using enhanced depth imaging optical coherence tomography.     

Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?

Background  

The Verteporfin in Photodynamic Therapy (VIP) Study failed to prove a statistically significant benefit for myopic choroidal neovascularization (CNV) at the end of the second year. Therefore, we wanted to evaluate whether the early effects seen under anti-VEGF treatment can be maintained over longer follow-up intervals.     

Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy

Purpose  

To report the efficacy of intravitreal bevacizumab for either recurrent or persistent serous changes originating from a persistent branching vascular network or secondary choroidal neovascularization after photodynamic therapy for polypoidal choroidal vasculopathy, despite regression of polypoidal lesions.     

Choroidal imaging in inherited retinal disease using the technique of enhanced depth imaging optical coherence tomography

Purpose  

The aim of this study is to image and describe the in vivo choroidal changes in various retinal dystrophies using the technique of enhanced depth imaging (EDI) optical coherence tomography (OCT) and to correlate these findings with the clinical appearance. Associations between choroidal change and genotype, visual acuity and results of retinal electrophysiology are also explored.     

Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses

Background  

Myopic maculopathy is the leading cause of subfoveal choroidal neovascularization (CNV) in patients under 50 years of age. New antiangiogenic drugs are being used off-label with varied therapeutic schedules to treat CNV. The aim of this study is to report the anatomical and visual outcomes of myopic choroidal neovascularization (CNV) treated by two different schedules with intravitreal bevacizumab.     

Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]

Background  

Reduced choroidal perfusion is hypothesized to play a role in the pathogenesis of normal tension glaucoma. Thus the impact of antiglaucomatous eye drops on ocular perfusion has been the focus of recent research and the subject of intensive investigations. The present study investigates whether topically applied latanoprost or bimatoprost influence ocular perfusion in patients with normal tension glaucoma and compares these effects with that changes detected after the treatment with dorzolamide.     

Choroidal metastasis from hepatocellular carcinoma,diagnosed by fine needle aspiration biopsy and treated by iodine-125 brachytherapy

Purpose  

To report a rare case of choroidal metastasis from hepatocellular carcinoma.     

The effect of intravitreal bevacizumab and transpupillary thermotherapy on choroidal metastases and literature review

Aims:

To represent the effects of transpupillary thermotherapy (TTT) and intravitreal bevacizumab on choroidal metastases and review the literature.

Settings and Design:

A retrospective, interventional, noncomparative case series.

Materials and Methods:

A retrospective, interventional, noncomparative case series of five eyes in three patients with choroidal metastases was conducted. Fundus findings of choroidal metastases were divided into two types: Solitary or diffuse type. The size of the tumor was termed small (<10 mm diameter), medium (10–15 mm diameter) or large (>15 mm diameter). All eyes received one session of TTT followed by 3 weekly intravitreal bevacizumab injections as an adjuvant therapy. The parameters of treatment for TTT were 1.2–3 mm spot size, 150–300 mW, 60 s with the whole lesion covered confluently. The changes in preoperative and postoperative best-corrected visual acuity (BCVA) were recorded. Serial color fundus photography and optical coherent tomography were performed to measure the treatment efficacy.

Results:

All eight choroidal metastases were solitary type. The size of six tumors was small, the size of one tumor was medium, and the size of one tumor was large. All five eyes of the three patients had improvement of BCVA after treatment. Fundus photos revealed tumor shrinkage and the mean shrinkage percentage was 61.27 ± 21.71%. Optical coherence tomography revealed complete resolution of serous retinal detachment. There was no recurrence after 6 months follow-up.

Conclusions:

TTT combined with intravitreal bevacizumab injections brought about beneficial effects in reducing tumor size and improving vision in all five eyes of the three patients. Despite the retrospective nature of our study, the absence of control group and the size limitation that, of course, limit the statistical power, TTT combined with intravitreal bevacizumab seems to be efficient in providing another cost-reducing and time-saving treatment option for patients with choroidal metastases. The antineoplastic properties of bevacizumab make it a viable adjunctive therapy. Studies with more cases and a longer follow-up period are warranted.     

Systemic Steroid-Pulse Therapy in a Patient with Idiopathic Choroidal Detachment: A Case Report

Aim

To report on the effectiveness of systemic steroid-pulse therapy in treating idiopathic choroidal detachment.

Case Presentation

Our patient developed idiopathic choroidal detachment after cataract surgery for pseudoexfoliation glaucoma and glaucoma filtration surgery. Systemic steroid-pulse therapy was performed, and the choroidal detachment resolved completely.

Conclusion

We suggest systemic steroid-pulse therapy as a treatment option for idiopathic choroidal detachment with low intraocular pressure.Key Words: Cataract surgery, Idiopathic choroidal detachment, Systemic steroid-pulse therapy     

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years

Background  

The combination of verteporfin photodynamic therapy (PDT) and anti-angiogenics has been shown to be safe and efficacious in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The purpose of this study is to demonstrate long-term prevention of vision loss and improvement in best-corrected visual acuity (BCVA) after treatment with one-time reduced-fluence-rate PDT followed by administration of ranibizumab on a variable dosing regimen over 24 months in patients with neovascular AMD. Secondary outcome measures included the change in central macular thickness (CMT), reinjection frequency, and safety.     

Verteporfin PDT for non-standard indications—a review of current literature

Background  

Verteporfin photodynamic therapy (PDT) is approved for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), as well as for subfoveal CNV due to pathologic myopia and ocular histoplasmosis syndrome. Verteporfin PDT addresses the underlying pathology of ocular vascular disorders through its angio-occlusive mechanism of action, which reduces both visual acuity loss and the underlying leakage associated with lesions. Verteporfin PDT has also been associated with encouraging treatment outcomes in case studies involving patients with choroidal vascular disorders such as polypoidal choroidal vasculopathy, central serous chorioretinopathy, choroidal haemangioma, angioid streaks, and inflammatory CNV, i.e. conditions currently considered as non-standard indications of verteporfin PDT. In many studies, outcomes were better than expected based on the natural courses of each of these conditions. Although the anti-vascular endothelial growth factor (VEGF) therapies, ranibizumab and pegaptanib, have been approved for CNV due to AMD, their role in these other choroidal vascular disorders remains to be established. We summarize current literature that has documented the use of verteporfin PDT in these conditions.     

Reduction in choroidal thickness of macular area in polypoidal choroidal vasculopathy patients after intravitreal ranibizumab therapy

Background

To evaluate changes in retinal and choroidal thickness changes after three intravitreal ranibizumab (IVR) injections for polypoidal choroidal vasculopathy (PCV) using enhanced depth-imaging-optical coherence tomography (EDI-OCT).

Methods

In this retrospective, observational case series, EDI-OCT was used to measure changes in choroidal thickness at nine points in a lattice shape in the macula before and after introductory-stage IVR.

Results

Choroidal thickness was decreased at all nine points in the lattice shape, but was significantly decreased only at the fovea.

Conclusion

The subfoveal choroidal thickness may be reduced by introductory-stage IVR in patients with PCV. In particular, choroidal thickness at the fovea was reduced during the early stage of treatment.     

Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab

Purpose  

To evaluate the efficacy of intravitreal bevacizumab (IVB) in eyes with polypoidal choroidal vasculopathy (PCV).